Shigellae are enteric pathogens that colonize and invade the human colonic mucosa, which typically results in febrile illness with dysentery. Because infections due to shigellae pose a serious health threat worldwide, priority has been placed on development of a safe oral vaccine which would elicit an intestinal secretory immunoglobulin A (IgA) response to critical Shigella antigens such as lipopolysaccharide (LPS) (4, 17, 20, 25) .
Heretofore, for practical reasons, demonstration of an immune response to oral vaccines relied on measurement of serum antibodies (3, 16) , which did not necessarily reflect mucosal responses (6, 12, 15, 18, 19, 21) . Direct measurement of intestinal secretory IgA antibodies (11, 15, 19, 23) has usually required the collection of intestinal fluids, which is cumbersome. Recently, several investigators reported the transient appearance of antigen-specific antibody-secreting cells (ASC), predominantly of the IgA isotype, in the peripheral blood subsequent to oral vaccination (6, 11, 13) or enteric infection (14) . In this context, circulating ASC are considered to be B lymphocytes that originated in the gut-associated lymphoid tissue and entered the blood, following sensitization to antigen, en route to various sites in the common mucosal immune system. By detecting ASC in the circulation following oral immunization, it is possible to quantitate the degree of stimulation of the intestinal mucosal immune system.
In this study we measured the 0-antigen-specific IgA-ASC response of volunteers as part of an evaluation of the immunogenicity and efficacy of candidate bivalent vaccine strain Salmonella typhi-Shigella sonnei 5076-1C, a derivative of attenuated S. typhi Ty2la, which contains the 120-megadalton plasmid of S. sonnei and expresses the LPS of both S. typhi and S. sonnei (10 (2) . Fourfold or greater rises in titer were considered significant (2, 15, 18, 19, 21) .
IgA-ASC were enumerated by using a modification of the enzyme-linked immunospot assay (5, 13, 24) four replicate wells of each of the four coating conditions (16 wells in all). Following a 3-h incubation at 37°C in a humidified chamber, wells were washed, and 100 ,ul of a 1:400 dilution of goat anti-human IgA-alkaline phosphatase conjugate (Kirkegaard-Perry Laboratories, Gaithersburg, Md.) was added to each. Wells were washed again after a 2-h incubation at 37°C, and to each well was added 100 ,ul of a molten agarose-substrate overlay (0.7% type I: low-EEO agarose [Sigma] with 0.05 mg of 5-bromo-4-chloro-3-indolyl phosphate and 0.1 mg of p-Nitro Blue Tetrazolium per ml; U.S. Biochemicals, Cleveland, Ohio). Following a 2-h incubation at room temperature or incubation overnight at 4°C, the presence of 0-antigen-specific IgA secreted by individual lymphocytes was visualized as dark-blue spots. Spots were counted by inverting the plates on the stage of a stereomicroscope and were recorded as ASC per 106 peripheral blood mononuclear cells.
Blood from 13 of 16 vaccinees was available for immunological studies. Only 8 of 13 and 4 of 13 vaccinees demonstrated a significant rise in serum IgA titer to S. sonnei and S. typhi 0 antigens, -respectively. In contrast, all 13 vaccinees developed an IgA response to S. sonnei 0 antigen if response was defined as transiently circulating IgA-ASC (compared with serum IgA response, P = 0.039 by the Fisher exact test with two-tailed hypothesis), and 10 of 13 developed an ASC response to S. typhi LPS as well (compared with serum IgA response, P = 0.047). Peak ASC responses occurred on day 9 for most individuals (Fig. 1) ; higher responses to either antigen were found on day 14 were studied in the preceding vaccination experiments) 10 had detectable ASC responses to the S. sonnei 0 antigen, and 6 of 12 controls showed such a response (Fig. 2) . No responses to S. typhi or V. cholerae LPS were found, demonstrating the specificity of the response. In this small challenge study there was a 100% correlation between the occurrence of clinical shigellosis and development of an ASC response, while serum IgA responses were seen in four of five and three of five ill vaccinees and controls, respectively, and in two of eight and three of seven nonill vaccinees and controls, respectively. Most ASC responses peaked on day 8 or 10 for both groups (one control had a peak value on day 4). Vaccination had a demonstrable priming effect. On day 8 after challenge, the mean vaccinee response increased rapidly; it remained high on day 10 in comparison with the smaller, more transient mean ASC response in controls (P < 0.05 for day 8 or 10 by the Wilcoxon rank sums test with one-tailed hypothesis).
In this study, we showed that Ty2la 5076-1C was an effective vehicle for stimulating an intestinal IgA response to S. sonnei 0 antigen. We also showed that the ASC procedure was a sensitive, specific, and relatively simple method for detecting this response. The (6, 7, 11, 22) .
The relationship between formation of an IgA-ASC response to S. sonnei 0 antigen and protection against S. sonnei disease is unknown. The level of ASC response generated by the vaccine in our study on the whole did not protect vaccinees against challenge, nor was there any correlation between protection and the peak values of individual responses. However, we did note that challenged controls had significantly higher peak ASC values as a result of illness than vaccinees had as a result of vaccination (P < 0.025; Wilcoxon rank sums test with two-tailed hypothesis). Dupont et al. (8) showed that the magnitude of the serum antibody response to 0 antigen following challenge with Shigella flexneri correlated with the severity of the clinical illness. The apparently stronger response to illness may be due to the generation of cytokines and T helper cells. The observation that prior illness due to Shigella infection can protect against homologous rechallenge (9; Herrington, in press) suggests that the magnitude of the IgA-ASC response may indeed be related to protection and that ASC measurements should be included in future Shigella vaccine evaluations.
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